In November 2017, Asana Medical, Inc. announced that they had formally changed their name to Regentys, as a more distinctive representation of their business model and underlying regenerative medicine technology.
Generex Biotechnology Partner Regentys Corporation Receives European Patent Approval for ECMH™ for Treatment of Ulcerative Colitis
Dec. 14, 2018
Generex Biotechnology Corporation (OTCQB:GNBT) announced today that Regentys Corporation (formerly Asana Medical, Inc.), a clinical stage regenerative medicine company contracted to become a subsidiary of Generex, was granted European Patent No. 2983616 entitled “Method And Composition For Treating Inflammatory Bowel Disease Without Colectomy.”
Generex Biotechnology Expands Medical Device & Wound Care Portfolio with Acquisition of Regentys Corporation
Nov. 29, 2018
Generex Biotechnology Corporation (OTCMKTS:GNBT) is pleased to announce that the company has signed a Binding Letter of Intent to acquire 51% of Regentys Corporation, a regenerative medicine company focused on developing treatments for patients with gastrointestinal (GI) disorders.
Regentys Named Finalist!
June 28, 2018
Lyfebulb LLC and UnitedHealth Group (NYSE:UNH) have selected 11 Patient Entrepreneur finalists who will compete in the “Empowering Patients: An Innovation Challenge” to earn the Lyfebulb and UnitedHealth Group Innovation Award.
Regentys, Cook Biotech to Collaborate in Developing, Delivering Unique Ulcerative Colitis Treatment
Feb. 14, 2018
Regentys (formerly Asana Medical, Inc.), a regenerative medicine company, today announced it will partner with Cook Biotech Inc., a world leader in cost-effective, advanced tissue-repair products, to develop a novel treatment for ulcerative colitis.
Regentys Names Dr. John F. Howes Vice President of Clinical and Regulatory Affairs
Jan. 9, 2018
Company Continues to Add Distinguished Medical Experts as Focus Pivots to First-In-Human Clinical Trials of its Novel, Regenerative Medicine Solution for Ulcerative Colitis.